Literature DB >> 14750179

MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma.

Derek Atkins1, Aldona Breuckmann, Gerd E Schmahl, Priska Binner, Soldano Ferrone, Frank Krummenauer, Stephan Störkel, Barbara Seliger.   

Abstract

Colorectal tumorigenesis has been associated with the progressive acquisition of a variety of genetic alterations. These include mutations of the Ki-ras proto-oncogene in codons 12 and 13, which account for 85% of genetic changes in colorectal cancer. In murine in vitro models of oncogenic transformation, an association between ras-mediated transformation and downregulation of different components of the MHC class I antigen processing machinery (APM) has been described. In order to investigate whether this association also exists in human tumors, 10 cases of high-grade intraepithelial neoplasia (HIN), as well as primary tumors and autologous lymph node metastases from 42 patients with colorectal carcinoma, were monitored by allele-specific restriction analysis for Ki-ras mutations. In parallel, APM component expression and tumor cell proliferation were analyzed by immunohistochemistry. In comparison to autologous colorectal mucosa, TAP1, LMP2 and tapasin loss was found in 68%, 67% and 80% of HIN, respectively. In contrast, impaired TAP1, LMP2 and tapasin expression was found in 42%, 42% and 63% of primary adenocarcinomas of stage III disease and in 63%, 47% and 79% of the matched lymph node metastases, respectively. More than 60% of colorectal tumor lesions with TAP1, LMP2 and/or tapasin defects displayed Ki-ras mutations. The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases. These data suggest that i) APM component deficiencies occur more frequently in Ki-ras-mutated colorectal carcinoma lesions and ii) APM abnormalities in conjunction with Ki-ras mutations appear to be associated with disease stage. These findings support the hypothesis that Ki-ras mutations may contribute to immune escape mechanisms of tumors by downregulating the MHC class I APM component expression. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14750179     DOI: 10.1002/ijc.11681

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  41 in total

1.  Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome.

Authors:  Qian Jiang; Hong-ya Pan; Dong-xia Ye; Ping Zhang; Lai-ping Zhong; Zhi-yuan Zhang
Journal:  Tumour Biol       Date:  2010-06-08

2.  Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.

Authors:  Juergen Bukur; Felix Herrmann; Diana Handke; Christian Recktenwald; Barbara Seliger
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

3.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.

Authors:  Yan Liu; Yoshihiro Komohara; Natalie Domenick; Masasuke Ohno; Maki Ikeura; Ronald L Hamilton; Craig Horbinski; Xinhui Wang; Soldano Ferrone; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2011-11-08       Impact factor: 6.968

4.  Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.

Authors:  Marco Bezzi; Nina Seitzer; Tomoki Ishikawa; Markus Reschke; Ming Chen; Guocan Wang; Caitlin Mitchell; Christopher Ng; Jesse Katon; Andrea Lunardi; Sabina Signoretti; John G Clohessy; Jiangwen Zhang; Pier Paolo Pandolfi
Journal:  Nat Med       Date:  2018-01-08       Impact factor: 53.440

5.  Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition.

Authors:  Yosuke Shionoya; Takayuki Kanaseki; Sho Miyamoto; Serina Tokita; Ayumi Hongo; Yasuhiro Kikuchi; Vitaly Kochin; Kazue Watanabe; Ryota Horibe; Hiroshi Saijo; Tomohide Tsukahara; Yoshihiko Hirohashi; Hiroki Takahashi; Noriyuki Sato; Toshihiko Torigoe
Journal:  Oncoimmunology       Date:  2017-01-03       Impact factor: 8.110

6.  The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy.

Authors:  Laurence M Wood; Zhen-Kun Pan; Matthew M Seavey; Geetha Muthukumaran; Yvonne Paterson
Journal:  Cancer Immunol Immunother       Date:  2011-11-06       Impact factor: 6.968

Review 7.  ProtEx technology for the generation of novel therapeutic cancer vaccines.

Authors:  Rich-Henry Schabowsky; Rajesh K Sharma; Shravan Madireddi; Abhishek Srivastava; Esma S Yolcu; Haval Shirwan
Journal:  Exp Mol Pathol       Date:  2009-01-31       Impact factor: 3.362

Review 8.  Inhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond.

Authors:  Marica Garziera; Giuseppe Toffoli
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

9.  Enhanced expression of interferon-gamma-induced antigen-processing machinery components in a spontaneously occurring cancer.

Authors:  Fulvia Cerruti; Marina Martano; Claudio Petterino; Enrico Bollo; Emanuela Morello; Renato Bruno; Paolo Buracco; Paolo Cascio
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

10.  Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas.

Authors:  Helen P Cathro; Mark E Smolkin; Dan Theodorescu; Vickie Y Jo; Soldano Ferrone; Henry F Frierson
Journal:  Cancer Immunol Immunother       Date:  2009-09-16       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.